Related Experiment Videos
[Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Which, when, how?]
1Departamento de Urgencias, Unidad Coronaria del Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, 14080 México, D.F.
Insights
Platelet activation is central to Acute Coronary Syndromes (ACS). Glycoprotein IIb/IIIa inhibitors offer a new treatment strategy for ACS patients, with specific indications and contraindications.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Context:
- Platelets play a central role in Acute Coronary Syndromes (ACS) pathophysiology, including activation, inflammation, and embolization.
- Platelet activation is crucial in initiating and recurring coronary artery thrombosis in ACS.
Purpose:
- To outline the role of platelet activation in ACS pathophysiology.
- To describe the indications and dosing of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors in ACS management.
- To identify patient groups unsuitable for GP IIb/IIIa inhibitor therapy.
Summary:
- Glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is critical in platelet activation during ACS.
- GP IIb/IIIa inhibitors represent a significant advancement in treating ACS, including elective interventions, unstable angina, and acute myocardial infarction.
- This paper details the use of available GP IIb/IIIa inhibitors and patient contraindications.
Impact:
- GP IIb/IIIa inhibitors provide a new therapeutic tool for initial ACS treatment.
- Understanding indications and contraindications optimizes the use of GP IIb/IIIa inhibitors.
- This strategy addresses key aspects of ACS management, from initial events to recurrence prevention.
Abstract:
The central action of platelets in pathophysiology of Acute Coronary Syndromes (ACS) has been outlined in relation to activation, inflammation and distal embolization. This platelet activation in ACS, plays the protagonistic role in the coronary artery thrombosis as the initial ischemic event, as well as in regards to its recurrence. The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is critical in this process. The introduction of this new class of drugs in the treatment of ACS has become a new tool in the initial treatment of the three main scenarios (elective intervention coronary procedures, unstable angina and acute myocardial infarction without ST elevation, and acute myocardial infarction either primary percutaneous angioplasty or in combination of low doses of thrombolytic agents) of this syndromes. This paper describes the indication and doses of the three commercially available GP IIb/IIIa inhibitors and describe the group of patients who are not candidates for this strategy.